Skip to main content
驱动力 logo

驱动力 — Investor Relations & Filings

Ticker · 920275 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 479 across all filing types
Latest filing 2024-04-28 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920275

About 驱动力

https://www.chinaedrive.com/

Drive Power Bio-tech specializes in the research, development, and manufacturing of functional additives designed for animal nutrition. The company focuses on hematopoietic technology, providing solutions that enhance hemoglobin synthesis, strengthen immune responses, and support intestinal health. Its product portfolio includes specialized nutritional supplements that optimize metabolic processes and improve growth performance. By leveraging biotechnological innovation, the company develops high-efficiency additives aimed at enhancing physiological health and production efficiency in large-scale agricultural environments.

Recent filings

Filing Released Lang Actions
华安证券股份有限公司关于广东驱动力生物科技集团股份有限公司使用闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a special verification opinion issued by the sponsor institution (华安证券股份有限公司) regarding the use of part of idle raised funds by 广东驱动力生物科技集团股份有限公司 for cash management. It details the background of the fundraising, the use and storage of the raised funds, the cash management investment products, the decision-making procedures, risk control measures, and the sponsor's verification opinion. The document references regulatory rules and approvals but does not contain full financial statements or comprehensive financial performance data. It is a regulatory compliance and verification report related to the use of raised funds, not an annual or interim financial report, earnings release, or capital update. The document length is 3742 characters, which is relatively short and focused on a specific verification opinion. Therefore, it fits best under Regulatory Filings (RNS) as a compliance and verification announcement rather than a full financial report or capital update.
2024-04-28 Chinese
2023年年度审计报告
Regulatory Filings
2024-04-28 Chinese
会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (audit firm) for the year 2023. It discusses the appointment, audit procedures, and assessment of the audit firm's independence and performance. It references audit reports and verification reports issued by the accounting firm but does not contain the full annual financial statements or the full annual report itself. The document length is short (1542 characters) and it is a standalone report on the audit firm's performance, not the full annual report. Therefore, it fits the category of Audit Report / Information (AR). FY 2023
2024-04-28 Chinese
关于使用部分闲置自有资金进行现金管理公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Guangdong Driving Force Biotechnology Group Co., Ltd. regarding the use of part of its idle funds for cash management. It details the purpose, amount, method, duration, decision-making process, risk analysis, and impact on the company. The document is relatively short (1404 characters) and focuses on a financing-related activity involving the company's capital management. It is not a full financial report, audit, or earnings release. It is not a regulatory filing or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities related to cash management of idle funds.
2024-04-28 Chinese
关于收到北京证券交易所问询函的公告
Regulatory Filings Classification · 95% confidence The document is a regulatory inquiry letter from the Beijing Stock Exchange's Listed Company Management Department to Guangdong Driving Force Biotechnology Group Co., Ltd. It discusses questions about the company's financial data restatement, accounting policy changes, and requests for explanations and confirmations regarding revenue recognition and internal controls. The document is an official regulatory communication requesting information and responses, not a financial report or earnings release itself. It is relatively short (1400 characters) and serves as a formal regulatory filing rather than a report or announcement of a report publication. Therefore, it fits best under Regulatory Filings (RNS).
2024-04-28 Chinese
2023年一季度报告（更正后）
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2023 First Quarter Report" of Guangdong Drive Biological Technology Group Co., Ltd. It contains detailed financial data for the quarter ending March 31, 2023, including balance sheet figures, income statement data, cash flow information, and explanations of significant changes. It also includes information about shareholders, related party transactions, and various company commitments and disclosures. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It is not an announcement of a report, nor a certification or a brief summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2024-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.